Cargando…
Technique of vessel-skeletonized parenchyma-sparing hepatectomy for the oncological treatment of bilobar colorectal liver metastases
BACKGROUND: To aid in the oncological management of multiple bilobar colorectal liver metastases (CRLMs), we describe a new surgical procedure, VEssel-Skeletonized PArenchyma-sparing Hepatectomy (VESPAH). STUDY DESIGN: Of 152 patients with CRLMs treated with hepatectomy, 33 patients had multiple bil...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933371/ https://www.ncbi.nlm.nih.gov/pubmed/34839388 http://dx.doi.org/10.1007/s00423-021-02373-9 |
_version_ | 1784671635251396608 |
---|---|
author | Umeda, Yuzo Nagasaka, Takeshi Takagi, Kosei Yoshida, Ryuichi Yoshida, Kazuhiro Fuji, Tomokazu Matsuda, Tatsuo Yasui, Kazuya Kumano, Kenjiro Sato, Hiroki Yagi, Takahito Fujiwara, Toshiyoshi |
author_facet | Umeda, Yuzo Nagasaka, Takeshi Takagi, Kosei Yoshida, Ryuichi Yoshida, Kazuhiro Fuji, Tomokazu Matsuda, Tatsuo Yasui, Kazuya Kumano, Kenjiro Sato, Hiroki Yagi, Takahito Fujiwara, Toshiyoshi |
author_sort | Umeda, Yuzo |
collection | PubMed |
description | BACKGROUND: To aid in the oncological management of multiple bilobar colorectal liver metastases (CRLMs), we describe a new surgical procedure, VEssel-Skeletonized PArenchyma-sparing Hepatectomy (VESPAH). STUDY DESIGN: Of 152 patients with CRLMs treated with hepatectomy, 33 patients had multiple bilobar liver metastases (≥8 liver metastases); their surgical procedures and clinical outcomes were retrospectively summarized and compared between those who underwent VESPAH and those who underwent major hepatectomy (Major Hx). RESULTS: Of the 33 patients, 20 patients were resected by VESPAH (the VESPAH group) and 13 patients by major hepatectomy (Major Hx group). The median number of CRLMs was 13 (range, 8–53) in the VESPAH group and 10 (range, 8–41) in the Major Hx group (P=0.511). No operative mortality nor severe morbidity was observed in either group. The VESPAH group showed earlier recovery of remnant liver function after surgery than the Major Hx group; the incidence of grade B/C post hepatectomy liver failure was 5% in the VESPAH group and 38% in the Major Hx group, P=0.048). Intrahepatic tumor recurrence was confirmed in 14 (70%) and 7 (54%) patients in the VESPAH and Major Hx groups, respectively (P=0.416). There was no significant difference in median overall survival (OS) after hepatectomy between the two groups; the median OS was 47 months in the VESPAH group and 33 months in the Major Hx group (P=0.481). The VESPAH group showed the higher induction rate of adjuvant chemotherapy within 2 months after surgery (P=0.002) and total number of repeat hepatectomy for intrahepatic recurrence (P=0.060) than the Major Hx group. CONCLUSIONS: VESPAH enables us to clear surgical navigation by hepatic vessel skeletonization and may enhance patient tolerability of not only adjuvant chemotherapy but also repeat hepatectomies during the patients’ lifetimes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00423-021-02373-9. |
format | Online Article Text |
id | pubmed-8933371 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-89333712022-04-01 Technique of vessel-skeletonized parenchyma-sparing hepatectomy for the oncological treatment of bilobar colorectal liver metastases Umeda, Yuzo Nagasaka, Takeshi Takagi, Kosei Yoshida, Ryuichi Yoshida, Kazuhiro Fuji, Tomokazu Matsuda, Tatsuo Yasui, Kazuya Kumano, Kenjiro Sato, Hiroki Yagi, Takahito Fujiwara, Toshiyoshi Langenbecks Arch Surg Original Article BACKGROUND: To aid in the oncological management of multiple bilobar colorectal liver metastases (CRLMs), we describe a new surgical procedure, VEssel-Skeletonized PArenchyma-sparing Hepatectomy (VESPAH). STUDY DESIGN: Of 152 patients with CRLMs treated with hepatectomy, 33 patients had multiple bilobar liver metastases (≥8 liver metastases); their surgical procedures and clinical outcomes were retrospectively summarized and compared between those who underwent VESPAH and those who underwent major hepatectomy (Major Hx). RESULTS: Of the 33 patients, 20 patients were resected by VESPAH (the VESPAH group) and 13 patients by major hepatectomy (Major Hx group). The median number of CRLMs was 13 (range, 8–53) in the VESPAH group and 10 (range, 8–41) in the Major Hx group (P=0.511). No operative mortality nor severe morbidity was observed in either group. The VESPAH group showed earlier recovery of remnant liver function after surgery than the Major Hx group; the incidence of grade B/C post hepatectomy liver failure was 5% in the VESPAH group and 38% in the Major Hx group, P=0.048). Intrahepatic tumor recurrence was confirmed in 14 (70%) and 7 (54%) patients in the VESPAH and Major Hx groups, respectively (P=0.416). There was no significant difference in median overall survival (OS) after hepatectomy between the two groups; the median OS was 47 months in the VESPAH group and 33 months in the Major Hx group (P=0.481). The VESPAH group showed the higher induction rate of adjuvant chemotherapy within 2 months after surgery (P=0.002) and total number of repeat hepatectomy for intrahepatic recurrence (P=0.060) than the Major Hx group. CONCLUSIONS: VESPAH enables us to clear surgical navigation by hepatic vessel skeletonization and may enhance patient tolerability of not only adjuvant chemotherapy but also repeat hepatectomies during the patients’ lifetimes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00423-021-02373-9. Springer Berlin Heidelberg 2021-11-27 2022 /pmc/articles/PMC8933371/ /pubmed/34839388 http://dx.doi.org/10.1007/s00423-021-02373-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Umeda, Yuzo Nagasaka, Takeshi Takagi, Kosei Yoshida, Ryuichi Yoshida, Kazuhiro Fuji, Tomokazu Matsuda, Tatsuo Yasui, Kazuya Kumano, Kenjiro Sato, Hiroki Yagi, Takahito Fujiwara, Toshiyoshi Technique of vessel-skeletonized parenchyma-sparing hepatectomy for the oncological treatment of bilobar colorectal liver metastases |
title | Technique of vessel-skeletonized parenchyma-sparing hepatectomy for the oncological treatment of bilobar colorectal liver metastases |
title_full | Technique of vessel-skeletonized parenchyma-sparing hepatectomy for the oncological treatment of bilobar colorectal liver metastases |
title_fullStr | Technique of vessel-skeletonized parenchyma-sparing hepatectomy for the oncological treatment of bilobar colorectal liver metastases |
title_full_unstemmed | Technique of vessel-skeletonized parenchyma-sparing hepatectomy for the oncological treatment of bilobar colorectal liver metastases |
title_short | Technique of vessel-skeletonized parenchyma-sparing hepatectomy for the oncological treatment of bilobar colorectal liver metastases |
title_sort | technique of vessel-skeletonized parenchyma-sparing hepatectomy for the oncological treatment of bilobar colorectal liver metastases |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933371/ https://www.ncbi.nlm.nih.gov/pubmed/34839388 http://dx.doi.org/10.1007/s00423-021-02373-9 |
work_keys_str_mv | AT umedayuzo techniqueofvesselskeletonizedparenchymasparinghepatectomyfortheoncologicaltreatmentofbilobarcolorectallivermetastases AT nagasakatakeshi techniqueofvesselskeletonizedparenchymasparinghepatectomyfortheoncologicaltreatmentofbilobarcolorectallivermetastases AT takagikosei techniqueofvesselskeletonizedparenchymasparinghepatectomyfortheoncologicaltreatmentofbilobarcolorectallivermetastases AT yoshidaryuichi techniqueofvesselskeletonizedparenchymasparinghepatectomyfortheoncologicaltreatmentofbilobarcolorectallivermetastases AT yoshidakazuhiro techniqueofvesselskeletonizedparenchymasparinghepatectomyfortheoncologicaltreatmentofbilobarcolorectallivermetastases AT fujitomokazu techniqueofvesselskeletonizedparenchymasparinghepatectomyfortheoncologicaltreatmentofbilobarcolorectallivermetastases AT matsudatatsuo techniqueofvesselskeletonizedparenchymasparinghepatectomyfortheoncologicaltreatmentofbilobarcolorectallivermetastases AT yasuikazuya techniqueofvesselskeletonizedparenchymasparinghepatectomyfortheoncologicaltreatmentofbilobarcolorectallivermetastases AT kumanokenjiro techniqueofvesselskeletonizedparenchymasparinghepatectomyfortheoncologicaltreatmentofbilobarcolorectallivermetastases AT satohiroki techniqueofvesselskeletonizedparenchymasparinghepatectomyfortheoncologicaltreatmentofbilobarcolorectallivermetastases AT yagitakahito techniqueofvesselskeletonizedparenchymasparinghepatectomyfortheoncologicaltreatmentofbilobarcolorectallivermetastases AT fujiwaratoshiyoshi techniqueofvesselskeletonizedparenchymasparinghepatectomyfortheoncologicaltreatmentofbilobarcolorectallivermetastases |